The study, published in the Journal of the National Cancer Institute found that in addition to protecting against 80% of cervical cancers, the new Gardasil-9 has the potential to protect against nearly 19,000 other cancers diagnosed in the United States.
The new 9-valent human papillomavirus (HPV) vaccine, can potentially prevent 80% of cervical cancers in the United States, if given to all 11- or 12-year-old children before they are exposed to the virus.
In addition to protecting against 80% of cervical cancers, the new 9-valent HPV vaccine, which includes 7 cancer causing HPV-types—16,18, 31, 33, 45, 52, and 58—has the potential to protect against nearly 19,000 other cancers diagnosed in the United States, including anal, oropharyngeal, and penile cancers. This is a 13% increase in protection against HPV-related cancers in comparison to the first vaccines on the market, Gardasil and Cervarix, which protected against HPV types 16 and 18. These findings come from a 7-center study published in the Journal of the National Cancer Institute. The CDC initiated the research effort, in conjunction with Cedars-Sinai.
Read the article on MedicalXpress: http://bit.ly/1HbBUaD
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More